BCA
CPRX

Biltmore Capital Advisors’s Catalyst Pharmaceutical CPRX Stock Holding History

Biltmore Capital Advisors’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-13,380
Closed -$71K – 69
2019
Q3 		$71K Sell
13,380
-3,000
-18% -$16K 0.02% 72
2019
Q2 		$63K Buy
16,380
+980
+6% +$4.23K 0.02% 71
2019
Q1 		$79K Buy
+15,400
New +$45.3K 0.03% 62

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Prudential Financial
Prudential Financial Newark, New Jersey $81.2B AUM 27.81% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return

Biltmore Capital Advisors's CPRX Position: Q4 2019 in Review

Biltmore Capital Advisors sold out of Catalyst Pharmaceutical (CPRX) in Q4 2019, closing a stake of 13,380 shares — an estimated $71K sold.

Biltmore Capital Advisors first reported a position in CPRX in Q1 2019 and held it in 3 quarters. The position peaked at $79K in Q1 2019. 130 funds tracked by Wall St. Rank hold CPRX as of Q4 2019.

  • Biltmore Capital Advisors reported no remaining Catalyst Pharmaceutical position as of Q4 2019 after selling out during the quarter.
  • Biltmore Capital Advisors sold 13,380 Catalyst Pharmaceutical shares in Q4 2019, an estimated $71K.
  • Biltmore Capital Advisors first reported a position in Catalyst Pharmaceutical in Q1 2019 and held it in 3 quarters.
  • Biltmore Capital Advisors's Catalyst Pharmaceutical position peaked at $79K in Q1 2019.
  • 130 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q4 2019.

Based on Biltmore Capital Advisors's 13F filing for Q4 2019, filed 10 Feb 2020.